Cheuk Tung Leung

US Patent:

20210284736, Sep 16, 2021

Filed:

May 20, 2021

Appl. No.:

17/325268

Inventors:

- Brighton MA, US
Rachel Rennard - Stoneham MA, US
Amanda Frank Oliphant - Boston MA, US
Cheuk Lun Leung - Quincy MA, US
Benjamin Jacob Wolf - Seattle WA, US
Ugur Eskiocak - Somerville MA, US
Pearl Bakhru - Ashland MA, US
Diana I. Albu - Windham NH, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

US Patent:

20200306374, Oct 1, 2020

Filed:

Jun 8, 2020

Appl. No.:

16/895239

Inventors:

- Cambridge MA, US
Paul Widboom - Lebanon NH, US
Michael March Schmidt - Wellesley MA, US
Jason M. Lajoie - Brighton MA, US
Cheuk Lun Leung - Quincy MA, US
Ugur Eskiocak - Somerville MA, US

International Classification:

A61K 39/395
C07K 16/28
A61P 35/00
A61K 39/00
A61K 35/17
C12N 15/79

Abstract:

The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

US Patent:

20200181266, Jun 11, 2020

Filed:

Nov 13, 2019

Appl. No.:

16/682756

Inventors:

- Cambridge MA, US
Rachel Rennard - Cambridge MA, US
Amanda Frank Oliphant - Cambridge MA, US
Cheuk Lun Leung - Cambridge MA, US
Benjamin Jacob Wolf - Cambridge MA, US
Ugur Eskiocak - Cambridge MA, US
Pearl Bakhru - Cambridge MA, US
Diana I. Albu - Cambridge MA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.